art5803
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 10, 2024 (NCT06575153)
Timeline
Indications
Mechanism of action
- Glutamate NMDA receptorINHIBITOR
Glutamate NMDA receptor inhibitor
- Glutamate receptor ionotropic, NMDA 2A (Grin2a) ↗
- Glutamate receptor ionotropic, NMDA 3B (Grin3b) ↗
- Glutamate receptor ionotropic, NMDA 2D (Grin2d) ↗
- Glutamate receptor ionotropic, NMDA 1 (Grin1) ↗
- Glutamate receptor ionotropic, NMDA 2B (Grin2b) ↗
- Glutamate receptor ionotropic, NMDA 2C (Grin2c) ↗
- Glutamate receptor ionotropic, NMDA3A (Grin3a) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07093333 | Phase 2 | Aug 1, 2025 | Arialys, Arialys Therapeutics |
| NCT06753955 | Phase 1 | Feb 11, 2025 | Arialys Therapeutics |
| NCT06575153 | Phase 1 | Sep 10, 2024 | Arialys Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arialys Therapeutics | For profit | 3 | 2 | 2 | 2024 |
| Arialys | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1